Although we demonstrate that anticoagulants such as the direct FXa inhibitor rivaroxaban improves APC function and the priming of T cell responses leading to attenuated tumor growth, we do not know whether these beneficial effects are generally applicable to human cancers with variable immunogenic profiles and whether synergistic effects will be seen also with other treatment combinations, including chemotherapy or radiation, which cause cell death and release of nucleic acids as part of their immunostimulatory activity. The gene discussed is APC; the disease is cancer.